Association of NPSR1 rs324981 polymorphism and treatment response to antidepressants in Chinese Han population with generalized anxiety disorder.

In previous studies, neuropeptide S (NPS) and its cognate receptor (NPSR) have been involved in the pathogenesis of anxiety disorders in previous studies. Here, we aimed to investigate the association of NPSR1 polymorphism with generalized anxiety disorder (GAD) and its treatment response in Chinese Han population. Three hundred and thirty seven patients and one hundred and seventy seven healthy controls were involved in our study for 8 weeks. Further, Hamilton Anxiety Scale (HAMA) was used to assess anxiety symptom at baseline and the 1st, 2nd, 4th, 8th week. And all participants were genotyped for NPSR1 (rs324981) variants by polymerase chain reaction. Using Repeated-measures analysis, it showed significant reduction on HAMA scores in patients treated with escitalopram (F = 1.03, P = 0.362) and venlafaxine (F = 0.27, P = 0.763) respectively through 8 weeks treatment. Additionally, patients with AA and TT homozygous genotypes treated with venlafaxine XR had a higher reduction of HAMA scores compared to AT heterozygotic carriers (F = 4.18, P = 0.004), while no significant differences were found in patients treated with escitalopram (F = 1.05, P = 0.383). Thus, our study provides preliminary evidence that NPSR1 AA and TT homozygous genotypes have better treatment responses to venlafaxine XR in Chinese GAD patients, but not to escitalopram. Further studies are needed to verify the observation.

KEYWORDS: {{ getKeywords(articleDetailText.words) }}